

Paul Edwards
Vice President of Chemistry

Paul Edwards has over 12 years of experience within the Pharmaceutical industry. Currently he is Vice President of Chemistry for **Boehringer Ingelheim** (Canada) Ltd., and is based in Laval, Quebec. He leads the Department of Chemistry in search of new antiviral medicines to treat HIV and HCV infection. Before taking up this role in January 2007 he held a number of other positions in the Pharmaceutical and Biotechnology industry. He was formally Director and Head of Chemistry for the biotechnology company Galapagos, based in Mechelen, Belgium. Prior to this he was Director of Medicinal Chemistry for Santhera pharmaceuticals (previously Graffinity) based in Heidelberg, Germany, and before this he spent nearly seven year at Pfizer Global Research & Development based in Sandwich, Kent in the United Kingdom. Here he held various positions in the Medicinal Chemistry and Lead Discovery Technologies Departments. His first industrial employment came at Oxford Asymmetry International Ltd., (now Evotec), based in Abingdon, Oxfordshire in the United Kingdom. Prior to taking up tenure in industry, he was firstly a SmithKline Beecham postdoctoral fellow with Regents' Professor Paul G. Gassman at the University of Minnesota, U.S.A, and then a postdoctoral fellow with Professor Steven V. Ley, FRS at the University of Cambridge in the United Kingdom.

In 1989 Paul was awarded a B.Sc honours degree in Chemistry, followed in 1992 by a Ph.D. degree in organic chemistry, both from the University of Leicester in the United Kingdom. In 2005 Paul received an MBA degree from the Open University in the United Kingdom. Inspired by the managing knowledge elective studied as part of his MBA degree, he worked with Oliver Schwabe to complete Verna Allee's ValueNet Works™ Course, and so become a certified value networks practitioner. Ever since qualification, he has been fascinated by the elucidation of intangible value within networks, primarily within the Pharmaceutical industry, and leveraging intangibles to enhance innovation within the modern drug discovery paradigm.

Paul is a Fellow of the Chartered Management Institute (FCMI) and a Chartered Manager (CMgr), is a Chartered Chemist and Fellow of the Royal Society of Chemistry (C.Chem., FRSC), a Chartered Scientist (C.Sci.), and a European Chemist (EurChem.).